

United States Patent and Trademark Office

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/692,553	10/23/2003	Donald L. Court	4239-66898	1179
7590 10/06/2005			EXAMINER	
KLARQUIST SPARKMAN, LLP			DUNSTON, JENNIFER ANN	
Suite 1600 One World Trade Center			ART UNIT	PAPER NUMBER
121 SW Salmon Street			1636	
Portland, OR 97204-2988			DATE MAILED: 10/06/2005	

Please find below and/or attached an Office communication concerning this application or proceeding.

·	Application No.	Applicant(s)				
	10/692,553	COURT ET AL.				
Office Action Summary	Examiner	Art Unit				
	Jennifer Dunston	1636				
The MAILING DATE of this communication appears on the cover sheet with the correspondence address Period for Reply						
A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 1 MONTH(S) OR THIRTY (30) DAYS, WHICHEVER IS LONGER, FROM THE MAILING DATE OF THIS COMMUNICATION. - Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication. - If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication. - Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133). Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).						
Status						
1) Responsive to communication(s) filed on	•					
•—	action is non-final.					
3) Since this application is in condition for allowar	Control of this application is in condition for allowance except for formal matters, prosecution as to the merits is					
closed in accordance with the practice under Ex parte Quayle, 1935 C.D. 11, 453 O.G. 213.						
Disposition of Claims						
4)⊠ Claim(s) <u>1-21</u> is/are pending in the application.						
4a) Of the above claim(s) is/are withdrawn from consideration.						
5) Claim(s) is/are allowed.						
6) Claim(s) is/are rejected.						
7) Claim(s) is/are objected to.	· · · · · · · · · · · · · · · · · · ·					
8) Claim(s) <u>1-21</u> are subject to restriction and/or election requirement.						
Application Papers						
9)☐ The specification is objected to by the Examiner.						
10) The drawing(s) filed on is/are: a) accepted or b) objected to by the Examiner.						
Applicant may not request that any objection to the		i i				
Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d).						
11) The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152.						
Priority under 35 U.S.C. § 119						
 12) Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f). a) All b) Some * c) None of: 1. Certified copies of the priority documents have been received. 2. Certified copies of the priority documents have been received in Application No. 3. Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)). * See the attached detailed Office action for a list of the certified copies not received. 						
Attachment(s) 1) Notice of References Cited (PTO-892) 2) Notice of Draftsperson's Patent Drawing Review (PTO-948) 3) Information Disclosure Statement(s) (PTO-1449 or PTO/SB/08) Paper No(s)/Mail Date	4) Interview Summary Paper No(s)/Mail D 5) Notice of Informal F 6) Other:					

DETAILED ACTION

Claims 1-21 are pending in the instant application.

Election/Restrictions

Restriction to one of the following inventions is required under 35 U.S.C. 121:

- I. Claims 1-13, drawn to a method for generating a vector for conditional knockout of a gene in a cell, comprising using homologous recombination to insert a nucleic acid encoding a selectable marker flanked by a pair of first recombining sites into a first site in a gene in a bacterial artificial chromosome, classified in class 435, subclass 91.4.
- II. Claims 14-17, drawn to a method for generating a non-human transgenic animal, comprising introducing a linearized vector comprising two recombining sites into an embryonic stem cell, classified in class 800, subclass 21.
- III. Claims 18-21, drawn to a method for introducing a nucleic acid sequence into an artificial chromosome without using drug selection by performing homologous recombination of a nucleotide sequence of interest in a host cells where the cell comprises a nucleic acid encoding a de-repressible promoter operably linked to a recombinase, classified in class 435, subclass 471.

The inventions are distinct, each from the other because of the following reasons:

The inventions of Groups I-III are biologically and functionally different and distinct from each other and thus one does not render the other obvious. The methods of Groups I-III

Art Unit: 1636

comprise steps which are not required for or present in the methods of the other groups: excising a nucleic acid encoding a selectable marker with a recombinase, wherein two recombining sites remain in the gene following excision of the nucleic acid encoding the selectable marker, and wherein recombination of the remaining recombination sites produces a nucleic acid sequence that cannot be transcribed into a functional protein (Group I); producing a transgenic animal from a stem cell (Group II); and introducing a nucleic acid sequence into a gene of interest on an artificial chromosome, comprising introducing into a cell a double-stranded nucleic acid comprising homology arms flanking a detectable nucleic acid sequence, wherein the detectable nucleic acid sequence does not encode a polypeptide that confers resistance of the cell to a drug (Group III). The end results of the methods are different: producing a vector for conditional knockout of a gene in a cell (Group I); producing a transgenic animal (Group II); and producing an artificial chromosome with a nucleic acid sequence introduced without a drug selection marker (Group III). Thus, the operation, function and effects of these different methods are different and distinct from each other. Therefore, the inventions of these different, distinct groups are capable of supporting separate patents.

Because these inventions are distinct for the reasons given above and have acquired a separate status in the art as shown by their different classification, restriction for examination purposes as indicated is proper. Further, there would be a serious search burden to search more than one group. The search for each method requires a separate text search of the patent and non-patent literature to search the method step(s) not shared with any other group. Therefore, the searches are not coextensive, and the additional searching that is required to search more than one group would impose a serious search burden.

Application/Control Number: 10/692,553

Art Unit: 1636

Applicant is advised that the reply to this requirement to be complete must include an election of the invention to be examined even though the requirement be traversed (37 CFR 1.143).

Applicant is reminded that upon the cancellation of claims to a non-elected invention, the inventorship must be amended in compliance with 37 CFR 1.48(b) if one or more of the currently named inventors is no longer an inventor of at least one claim remaining in the application. Any amendment of inventorship must be accompanied by a request under 37 CFR 1.48(b) and by the fee required under 37 CFR 1.17(i).

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Jennifer Dunston whose telephone number is 571-272-2916. The examiner can normally be reached on M-F, 9 am to 5 pm.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Remy Yucel can be reached at 571-272-0781. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

Any inquiry of a general nature or relating to the status of this application or proceeding should be directed to (571) 272-0547.

Patent applicants with problems or questions regarding electronic images that can be viewed in the Patent Application Information Retrieval system (PAIR, http://pair-direct.uspto.gov) can now contact the USPTO's Patent Electronic Business Center (Patent EBC) for assistance. Representatives are available to answer your questions daily from 6 am to midnight (EST). The toll free number is (866) 217-9197. When calling please have your application serial or patent number, the type of document you are having an image problem with,

Application/Control Number: 10/692,553

Art Unit: 1636

the number of pages and the specific nature of the problem. The Patent Electronic Business

Center will notify applicants of the resolution of the problem within 5-7 business days.

Applicants can also check PAIR to confirm that the problem has been corrected. The USPTO's

Patent Electronic Business Center is a complete service center supporting all patent business on

the Internet. The USPTO's PAIR system provides Internet-based access to patent application

status and history information. It also enables applicants to view the scanned images of their own

application file folder(s) as well as general patent information available to the public.

For all other customer support, please call the USPTO Call Center (UCC) at 800-786-

9199.

Jennifer Dunston Examiner Art Unit 1636

jad

TERRY MCKELVEY
PRIMARY EXAMINER

Page 5